Capricor Therapeutics Inc... (CAPR)
Capricor Therapeutics Statistics
Share Statistics
Capricor Therapeutics has 45.47M shares outstanding. The number of shares has increased by 44.81% in one year.
| Shares Outstanding | 45.47M |
| Shares Change (YoY) | 44.81% |
| Shares Change (QoQ) | 39.74% |
| Owned by Institutions (%) | 25.29% |
| Shares Floating | 39.98M |
| Failed to Deliver (FTD) Shares | 2.98K |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 7.59M, so 16.69% of the outstanding shares have been sold short.
| Short Interest | 7.59M |
| Short % of Shares Out | 16.69% |
| Short % of Float | 18.98% |
| Short Ratio (days to cover) | 6.57 |
Valuation Ratios
The PE ratio is -5.88 and the forward PE ratio is -18.15. Capricor Therapeutics's PEG ratio is 0.2.
| PE Ratio | -5.88 |
| Forward PE | -18.15 |
| PS Ratio | 5.2 |
| Forward PS | 2.2 |
| PB Ratio | 5.79 |
| P/FCF Ratio | -4.74 |
| PEG Ratio | 0.2 |
Enterprise Valuation
Capricor Therapeutics Inc. has an Enterprise Value (EV) of 121.86M.
| EV / Earnings | -5.47 |
| EV / Sales | 4.84 |
| EV / EBITDA | -5.3 |
| EV / EBIT | -5.06 |
| EV / FCF | -4.41 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.1.
| Current Ratio | 1.63 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 9 |
| Cash Flow / Debt | -11.45 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.99% and return on capital (ROIC) is -96.94%.
| Return on Equity (ROE) | -0.99% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -96.94% |
| Revenue Per Employee | $249,287.78 |
| Profits Per Employee | $-220,668.73 |
| Employee Count | 101 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 191.65% in the last 52 weeks. The beta is 4.09, so Capricor Therapeutics's price volatility has been higher than the market average.
| Beta | 4.09 |
| 52-Week Price Change | 191.65% |
| 50-Day Moving Average | 14.3 |
| 200-Day Moving Average | 10.95 |
| Relative Strength Index (RSI) | 43.87 |
| Average Volume (20 Days) | 1.15M |
Income Statement
In the last 12 months, Capricor Therapeutics had revenue of 25.18M and earned -22.29M in profits. Earnings per share was -0.83.
| Revenue | 25.18M |
| Gross Profit | 24.11M |
| Operating Income | -24.08M |
| Net Income | -22.29M |
| EBITDA | -23.01M |
| EBIT | -24.08M |
| Earnings Per Share (EPS) | -0.83 |
Balance Sheet
The company has 14.69M in cash and 2.24M in debt, giving a net cash position of 12.46M.
| Cash & Cash Equivalents | 14.69M |
| Total Debt | 2.24M |
| Net Cash | 12.46M |
| Retained Earnings | -159.37M |
| Total Assets | 92.95M |
| Working Capital | -20.39B |
Cash Flow
In the last 12 months, operating cash flow was -25.6M and capital expenditures -2.05M, giving a free cash flow of -27.64M.
| Operating Cash Flow | -25.6M |
| Capital Expenditures | -2.05M |
| Free Cash Flow | -27.64M |
| FCF Per Share | -1.03 |
Margins
Gross margin is 95.75%, with operating and profit margins of -95.63% and -88.52%.
| Gross Margin | 95.75% |
| Operating Margin | -95.63% |
| Pretax Margin | -88.52% |
| Profit Margin | -88.52% |
| EBITDA Margin | -91.39% |
| EBIT Margin | -95.63% |
| FCF Margin | -109.79% |
Dividends & Yields
CAPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.09% |
| FCF Yield | -4.46% |
Analyst Forecast
The average price target for CAPR is $32.5, which is 138.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.5 |
| Price Target Difference | 138.6% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Jun 5, 2019. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 5, 2019 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -250.36 |
| Piotroski F-Score | 2 |